Search results
Results from the WOW.Com Content Network
Endometrial cancer appears most frequently during perimenopause (the period just before, just after, and during menopause), between the ages of 50 and 65; [20] overall, 75% of endometrial cancer occurs after menopause. [2] Women younger than 40 make up 5% of endometrial cancer cases and 10–15% of cases occur in women under 50 years of age.
Treatment may include a combination of surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. [1] [2] Just over 80% of women survive more than 5 years following diagnosis. [8] In 2015 about 3.8 million women were affected globally and it resulted in 90,000 deaths.
Endometrial hyperplasia is a condition of excessive proliferation of the cells of the endometrium, or inner lining of the uterus.. Most cases of endometrial hyperplasia result from high levels of estrogens, combined with insufficient levels of the progesterone-like hormones which ordinarily counteract estrogen's proliferative effects on this tissue.
Uterine hyperplasia, or enlarged uterus, is a medical symptom in which the volume and size of the uterus in a female is abnormally high. It can be a symptom of medical conditions such as adenomyosis , uterine fibroids , ovarian cysts , and endometrial cancer .
Both endometriosis and adenomyosis occur when the lining of the uterus grows out of place, but there are major differences between the two Adenomyosis: 5 things you need to know about the ‘evil ...
Treatment of postmenopausal women with 2.5 or 5 mg/day MPA in combination with estradiol valerate for two weeks has been found to rapidly increase circulating MPA levels, with steady-state concentrations achieved after three days and peak concentrations occurring 1.5 to 2 hours after ingestion.
A stronger suppression of testosterone levels was observed in men following daily treatment with a combined oral contraceptive containing 50 μg ethinylestradiol and 0.5 mg norgestrel for 9 days. [8] However, investigation revealed that the progestin was the more important component responsible for the suppression in testosterone levels. [ 8 ]
Aromatase excess syndrome (AES or AEXS) is a rarely diagnosed genetic and endocrine syndrome which is characterized by an overexpression of aromatase, the enzyme responsible for the biosynthesis of the estrogen sex hormones from the androgens, in turn resulting in excessive levels of circulating estrogens and, accordingly, symptoms of hyperestrogenism.